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Abstract
Dengue virus infection is a leading cause of morbidity among children in the Philippines in
recent years. In order to investigate the association of HLA Class I and I aleles and dengue
disease severity in a cohort of Filipino children, we performed a case control study in 2 hos-
pitals in Metro Manila from June 2008 to December 2009. A total of 250 laboratory con-
firmed dengue patients and 300 healthy individuals aged 5 to 15 years old were typed for
HLA-A, B and DRB1 aleles. The frequency of HLA-A*33:01 was significantly decreased in
severe dengue (DHF/ DSS;Pc= 0.0016) and DSS (Pc= 0.0032) compared to the back-
ground population. These findings support a previous study that this alele may confer pro-
tection against the severe form of dengue and provide the first evidence of HLA association
with dengue in the Philippines. Future studies should be directed in investigating the possi-
ble mechanisms of protection.
Introduction
Dengue has become the most rapidly spreading mosquito-borne viral disease in the world,
with a 30-fold increase in incidence in the last 50 years [1]. The disease is caused by four dis-
tinct, but closely related viruses (denoted dengue types 1–4) and can manifest in a range of
symptoms, from the mild flu-like ilness and rash (dengue fever, DF) to a severe, potentialy
fatal disease characterized by vascular leakage, hemorrhage, and sometimes hypovolemic shock
(dengue hemorrhagic fever, DHF or dengue shock syndrome, DSS) [2]. Al four serotypes of
dengue virus can cause DF and DHF, with the majority of DHF cases occurring in children [3].
Dengue fever is hyper-endemic in the Philippines, with al four serotypes co-circulating.
During the period January 1 to September 7, 2013, the National Epidemiology Center of the
Department of Health reported 117, 658 dengue cases from sentinel hospitals nationwide, with
40% of these cases belonging to the 1–10 years old age group [4]. Since the report of the first
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DHF epidemic in Manila in 1954 [5], epidemics have been occurring in diferent parts of the
country, particularly in Metro Manila and other urban areas.
A central part of the pathogenesis of DHF and DSS is the loss of endothelial integrity, be-
lieved to be the result of an abnormal immune response and a disturbance in immune regula-
tion [6]. Although the exact mechanisms leading to these observations remain unclear, host
and viral factors have been considered to play a role in progression to severe disease. Epidemio-
logic and laboratory studies have shown that prior infection with a heterologous viral serotype
predisposes progression to DHF, a phenomenon known as antibody-dependent enhancement
[7–9]. Viral virulence factors might also determine disease severity: Den-2 was reported to
cause more severe infections in Thailand and Vietnam, while more than one serotype was im-
plicated in severe dengue cases in Latin America [10]. Studies on human genetic determinants
such as single nucleotide polymorphisms (SNPs) and polymorphisms in the human leukocyte
antigen (HLA) genes suggest that they play an important role in susceptibility or protection to
dengue disease [6,11–16]. Although a number of HLA Class I and Class I aleles were found
to be associated with DHF/DSS, these might vary according to the study population. To date,
there has been no report on the HLA polymorphisms in dengue-infected individuals in the
Philippines. This study determined the HLA-A, -B and -DRB1 polymorphisms in Filipino chil-
dren and their possible association with severity of dengue infections in the country.
Methods
Study Population
This study was conducted in two hospitals in Metro Manila, the Philippines: the Research Insti-
tute for Tropical Medicine (RITM), located in Alabang, Muntinlupa City, and the Philippine
Children’s Medical Center (PCMC) in Quezon City. Suspected dengue patients admited in
these hospitals from June 2008 to December 2009 who satisfied the folowing criteria were en-
roled in the study: age 5 to 15 years old, Filipino Malay race, non-relatedness to other study
subjects and no blood transfusion in the past 6 months prior to their admission or consultation
to the hospital. Writen informed consent was obtained from the parents or legal guardians of
al study participants. In addition, assent was also obtained from patients who are 7 years old
and above. The study was approved by the institutional review boards of RITM and PCMC.
Patient clinical data
Medical histories, clinical symptoms and laboratory test results were recorded on case report
forms (CRFs). Patients were classified according to disease severity, either as dengue fever
(DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) based on the estab-
lished WHO criteria [17] after reviewing the CRFs of the patients. Shock was defined as having
pulse pressure of less than or equal to 20mmHg, according to the 2009 WHO guidelines [1].
In addition to the patients’classification according to established WHO criteria, the presence
of warning signs as listed in the 2009 revised dengue classification system were also identified
from the data on the CRFs [1]. These warning signs include abdominal pain or tenderness,
persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy/restlessness, liver en-
largement>2cm (hepatomegaly) and increase in hematocrit (HCT) concurrent with a rapid
decrease in platelet count. Warning signs were defined as folows, which were adopted and
modified from Narvaez et al (2011) [18]: Abdominal pain or tenderness: abdominal tenderness
or continuous pain (not intermitent), on some occasions difuse. Persistent vomiting: at least
6 episodes of vomiting in 24 hours, or defined as Grade 3 and above in the Common Toxicity
Criteria Manual [19]. Clinical fluid accumulation: pleural efusion and ascites diagnosed clini-
caly or with imaging techniques (ultrasound for ascites, galbladder wal thickening, and
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pleural efusion, and/or X-rays for pleural efusion). Mucosal bleeding: bleeding gums or con-
junctiva, epistaxis, vaginal bleeding, bleeding from digestive, respiratory or urinary system
(kidneys); mucosa defined as respiratory, vaginal, digestive, conjunctival and urinary tract mu-
cosa. Lethargy or restlessness: clinical evaluation of patient’s status. Hepatomegaly: the liver
edge palpated by the clinician more than 2 cm below the costal margin. Increased hematocrit
concurrent with rapid decrease in platelet count: increase of 20% in hematocrit compared to
normal values for age and sex [20] concurrent with platelet count 100,000 cels/mm3. The
warning signs were noted anytime during the hospital stay of the patients.
Sample colection and laboratory diagnosis
Blood samples were colected from patients at the time of study enrolment. Diagnostic tests for
dengue virus infection included detection of IgM and IgG antibodies by serology or detection
of viral RNA by reverse-transcriptase polymerase chain reaction (RT-PCR). IgM and IgG anti-
bodies were detected in patients’sera using the PanBio Dengue IgM and IgG Capture Antibody
test (Inverness Medical Innovations, Queensland, Australia). The cases were determined as pri-
mary infection if the IgM/IgG ratio was greater than 1.78 [21], and consequently, as secondary
infection if the ratio was less than 1.78 [22].
Viral RNA was extracted from acute serum samples using QIAamp Viral RNA Mini kit
(QIAgen, Hilden, Germany). A widely used hemi-nested RT-PCR assay, developed by Lan-
cioti et al. [23] targeting the C and pre-M regions of the viral genome, was used for dengue
virus detection and serotyping. A modification of this protocol was adopted in this study,
which used TS1bis primer instead of TS1 to detect Den-1 [24].
Population background
Blood samples from healthy, unrelated children from a community in Quezon City and a menin-
gococcemia vaccine eficacy study in Muntinlupa City formed the background population group.
The samples were colected specificaly for this study, the protocol of which was approved by the
institutional review boards of RITM, PCMC and NEKKEN, Nagasaki University. As with the den-
gue patients, writen consent was obtained from parents or legal guardians of al healthy subjects,
and assent of children 7 years old and above was also obtained in addition to the consent. The
samples from the vaccine study were colected before any vaccine was given to the children. The
sera of the background population group were tested for Dengue IgG antibodies using the PanBio
Dengue IgG Capture Antibody test (Inverness Medical Innovations, Queensland, Australia).
HLA typing
For both dengue patient and population background samples, HLA-A, -B and -DRB1 were
typed with a microbead sequence-specific oligonucleotide assay (SSO) using LAB type SSO kits
(One Lambda, CA, USA) and LAB Scan 100 system (One Lambda, CA, USA). The IS 2.3 typ-
ing software and HLA Fusion v.1.2.1 software were used for genotype assignment.
Statistical analysis
Phenotype frequencies of patient groups were compared pairwise with the population control
group to determine possible association. Diferences in frequencies were analyzed by the
chi-square test or Fisher’s exact test (two-sided) using the StatsDirect statistical software
(StatsDirect Ltd., UK), version 2.7.8. The odds ratio (OR) with corresponding 95% Confidence
Intervals (95% CI) was computed. P values were corrected using the Bonferroni method, by
multiplying with the number of major aleles whose frequencies exceed 5% in either the patient
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or population group, yielding the corrected P value (Pc). The correction factors were 11 for
HLA-A, 18 for HLA-B and 14 for HLA-DRB1. Diferences yielding P values or Pc values (for
alele frequencies) less than 0.05 were considered significant.
Results
Clinical characteristics of the study population
A total of 250 laboratory confirmed dengue patients were included in the study analysis: 220 of
these were positive by IgM serology, 132 were positive by RT-PCR and 102 were positive for
both tests. The mean age was 9.8, and males comprised 54.4% of patients. The proportion of
cases determined as DSS, DHF and DF using the WHO (1997) classification is shown in
Table 1. Patients who went into shock (DSS cases) accounted for majority of the patients in
this study (122 or 48.8%), folowed by DF cases (94 or 37.6%), while DHF cases made up only
13.6% of the patients (Table 1). Most of the patients had secondary infection (78.5%), and the
percentage of patients with secondary infection was significantly higher in those with DSS
compared to the DF group (OR = 2.65,P= 0.005), but was not significant between DSS and
DHF, or between the DHF and DF cases.
The most common warning sign in this group of patients was abdominal pain or tenderness
(detected in 77% of the patients), which was significantly higher in the DSS group compared to
the DF group (OR = 3.89,P<0.0001). Likewise, clinical fluid accumulation, mucosal bleeding
and increase in hematocrit with rapid decrease in platelet count were significantly higher in
DSS compared to the DF group (Table 1). On the other hand, only 11 out of 242 patients had
liver enlargement>2cm or hepatomegaly (4.5%,Table 1) in this study population.
Table 1. Demographic, clinical and laboratory features of dengue patients classified using WHO 1997 classification.
DSS (n = 122) DHF (n = 34) DF (n = 94) Total (n = 250) Control (n = 300)
Mean Age (years)±SD 9.5±2.61 10.6±2.57 10.1±3.05 9.8±2.81 10.0±3.04
Male:Female 64:58 22:12 50:44 136:114 158:142
Secondary infection (%)a 95/112 (84.8) 29 (85.3) 59/87 (67.8) 183/233 (78.5) n.d.
Presence of warning signs (%) n.d.
Abdominal pain/tendernessb 106/121 (87.6) 26 (76.5) 59/93 (64.5) 191/248 (77.0) n.d.
Persistent vomiting n.d.c n.d. n.d. n.d. n.d.
Clinicalfluid accumulationb 52 (42.6) 13 (38.2) 2 (2.1) 67 (26.8) n.d.
Mucosal bleedingb 47 (38.5) 11 (32.4) 19 (20.2) 77 (30.8) n.d.
Lethargy, restlessness 9 (7.4) 1 (2.9) 2 (2.1) 12 (4.8) n.d.
Liver enlargement>2 cm 7/118 (5.9) 1/32 (3.1) 3/92 (3.3) 11/242 (4.5) n.d.
Increase in hematocrit with rapid decrease in platelet countb 29 (23.8) 7 (20.6) 6 (6.4) 42 (16.8) n.d.
No. of patients positive for serotyping 64 20 46 130 n.d.
Den-1 (%) 3 (4.7) 1 (5) 5 (10.9) 9 (6.9) n.d.
Den-2 (%) 11 (17.2) 3 (15) 11 (23.9) 25 (19.2) n.d.
Den-3 (%) 50 (78.1) 15 (75) 30 (65.2) 95 (73.1) n.d.
Den-4 (%) 0 1 (5) 0 1 (0.8) n.d.
aDSS vs DF, OR = 2.65 (1.3–5.3),P= 0.005
bDSS vs. DF, OR = 3.89 (2.0–7.7),P<0.0001 (Abdominal pain/tenderness); DSS vs. DF, OR = 34.17 (8.0 to 145.1),P<0.0001, DHF vs. DF,P<0.0001
(Clinicalfluid accumulation); DSS vs. DF, OR = 2.47 (1.3–4.6),P= 0.0037 (Mucosal bleeding); DSS vs. DF, OR = 4.57(1.8–11.5),P= 0.0004, DHF vs.
DF,P= 0.0405 (Increase in hematocrit with decrease in platelet count)
cn.d. = not determined
doi:10.1371/journal.pone.0115619.t001
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Den-3 was the predominant serotype (73.1%), folowed by Den-2 (19.2%) and Den-1 (6.9%,
Table 1). However, infection with a particular serotype was not associated with disease severity
in this study (data not shown).
The mean age of the background population group was 10.0, with males accounting for 53%
of the subjects (Table 1). Moreover, eight out of 300 (2.7%) healthy subjects were seropositive
for dengue IgG antibodies.
Phenotype frequencies of HLA-A, HLA-B and HLA-DRB1
The major aleles in this study, defined as aleles with more than 5% phenotype frequencies in
either the patient or population background group, are as folows: HLA-A02:01, 02:03, 02:06,
02:27, 11:01, 24:02, 24:03, 24:07, 24:10, 33:01, 34:01; HLA-B07:05, 15:01, 15:02, 15:07, 15:13,
15:21, 15:35, 18:01, 35:01, 35:05, 38:02, 40:01, 40:02, 46:01, 48:01, 51:01, 58:01; HLA-DRB1
03:01, 04:03, 04:05, 04:07, 04:10, 07:01, 08:03, 09:01, 11:01, 12:02, 14:01, 14:05, 15:01, 15:02.
Association of HLA Aleles with Severe Dengue
The phenotype frequencies of HLA-A, HLA-B and HLA–DRB1 in the severe dengue (DSS and
DHF), DF and background population groups are listed inTable 2. HLA-A33:01 was associ-
ated with a reduced risk of developing severe dengue (DSS/DHF) when compared to the back-
ground population (OR = 0.2,Pc= 0.0022). The HLA-B aleles 07:05, 38:02 and 58:01 and
HLA-DRB1 03:01 were also reduced in the severe dengue group compared to the population
background group, but these were not statisticaly significant after correction. On the other
hand, HLA-B aleles 35:01 and 51:01 and HLA-DRB112:02 were associated with a higher risk
of developing severe dengue compared to the background population. However, these aleles
also did not withstand correction. When comparing DF to the population background group,
HLA-A 02:03 was increased in the patient group, while HLA-B48:01 and HLA-DRB1
03:01 were reduced in the patient group, but again, these were not statisticaly significant.
Table 2. Phenotype frequencies of HLA-A, HLA-B and DRB1 and their association with dengue disease severity.
Phenotype DSS and DHF
No. (%)
DF No. (%)a Control No. (%)b DSS and DHF vs Control DF vs Control DSS and DHF vs DF
OR (95% CI) P value Pcb OR (95% CI) P value Pc OR (95% CI) P value Pc
A locus n = 153 n = 92 n = 296
02:03 2 (1.3) 5 (5.4) 3 (1.0) 1.3 (0.2–7.8) >0.999 - 5.6 (1.3–24) 0.021 0.231 0.2 (0.04–1.2) 0.107 -
33:01 3 (2.0) 5 (5.4) 34 (11.5) 0.2 (0.05–0.5) 0.0002 0.0022 0.4 (0.2–1.2) 0.086 - 0.3 (0.08–1.5) 0.156 -
B locus n = 155 n = 93 n = 297
07:05 3 (1.9) 4 (4.3) 18 (6.1) 0.3 (0.09–1.1) 0.0439 0.790 0.7 (0.2–2.1) 0.551 - 0.4 (0.1–2.0) 0.311 -
35:01 23 (14.8) 7 (7.5) 24 (8.1) 2.0 (1.1–3.6) 0.03 0.540 0.9 (0.4–2.2) 0.890 - 2.1 (0.9–5.2) 0.09 -
38:02 34 (21.9) 24 (25.8) 91 (30.6) 0.6 (0.4–1.0) 0.0489 0.880 0.8 (0.5–1.3) 0.378 - 0.8 (0.4–1.5) 0.489 -
48:01 11 (7.1) 2 (2.2) 24 (8.1) 0.9 (0.4–1.8) 0.7257 - 0.3 (0.06–1.1) 0.0365 0.657 3.5 (0.8–16.0) 0.0935 -
51:01 16 (10.3) 6 (6.5) 15 (5.1) 2.2 (1.0–4.5) 0.0425 0.765 1.3 (0.5–3.4) 0.595 - 1.7 (0.6–4.4) 0.312 -
58:01 5 (3.2) 4 (4.3) 28 (9.4) 0.3 (0.1–0.8) 0.0131 0.236 0.4 (0.1–1.3) 0.112 - 0.7 (0.2–2.8) 0.667 -
DRB1 locus n = 153 n = 90 n = 300
03:01 4 (2.6) 2 (2.2) 24 (8) 0.3 (0.1–0.9) 0.0204 0.286 0.3 (0.06–1.1) 0.0447 0.626 1.2 (0.2–6.6) 0.886 -
12:02 56 (36.6) 27 (30) 79 (26.3) 1.6 (1.1–2.5) 0.0256 0.358 1.2 (0.7–2.0) 0.493 - 1.3 (0.8–2.4) 0.299 -
aThe number for each HLA locus shows the number of successfuly typed samples
bCorected P-values (Pc) were only calculated for loci with P-values less than 0.05
doi:10.1371/journal.pone.0115619.t002
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Association of HLA Aleles with the development of shock
Table 3shows the phenotype frequencies of patients which developed shock (DSS), those with
severe dengue but without shock (DHF) and the background population group. HLA-A33:01
was significantly reduced in dengue patients which developed shock compared to the back-
ground population (OR = 0.1,Pc= 0.0044). The HLA-B aleles 38:02, 58:01 and DRB1 alele
03:01 were reduced in the DSS group compared to the population background, but this
was not statisticaly significant after correction. HLA-B 35:01 was associated with a higher
risk of developing DSS compared to the background population; however, this was also not
statisticaly significant.
Discussion
Dengue has become the most important vector-borne disease in the Philippines, but there is lit-
tle published data on the clinical characteristics of the disease, and none on host factors afect-
ing this disease in the population. This study describes the clinical characteristics of dengue
patients aged 5 to 15 years old in 2 hospitals in Metro Manila from June 2008 to December
2009, and presents the first evidence of possible genetic factors influencing disease severity in
the Filipino population.
Majority of the patients in the study developed shock (DSS, 48.8%), folowed by mild DF
(37.6%) and DHF but without shock (13.6%;Table 1). This is in contrast to an earlier study
done in 1999–2001 in another hospital in Metro Manila, in which most of the patients had DF
(66.6%), and of those that developed DHF, only 3/120 patients were classified as DHF II and
IV [25]. The 7–10 year time diference between study periods and the hospital seting may
have contributed to the diference in proportions of severe dengue between our studies. The
number of dengue cases has risen more than 500% from 1999 to 2009, with a corresponding
~300% increase in deaths during this period [26]. In addition to the rise in the number of cases,
the earlier study was also conducted in a private hospital where dengue patients are seen earlier,
while our study was conducted in 2 government referral hospitals where patients are usualy
admited when they are in DHF stage 1 or 2, and DF cases are mostly seen in the outpatient de-
partment. Nevertheless, even with this diference, abdominal pain is an important finding in
both of our studies, and it was also increased in patients with the more severe form of dengue.
Although the pathogenesis of abdominal pain in dengue is not clearly understood, previous
studies have implicated hepatitis, acalculous cholecystitis, acute pancreatitis and hepatomegaly
Table 3. Phenotype frequencies of HLA-A, HLA-B and DRB1 and their association with presence or absence of shock in severe dengue.
Pheno-type DSS No.a(%) DHF No.a(%) Control No.a(%) DSS vs DHF DSS vs Control DHF vs Control
OR (95% CI) P value Pcb OR (95% CI) P value Pc OR (95% CI) P value Pc
A locus n = 120 n = 34 n = 296
33:01 2 (1.7) 1 (2.9) 34 (11.5) 0.6 (0.05–6.4) 0.530 - 0.1 (0.03–0.6) 0.0004 0.0044 0.2 (0.03–1.8) 0.116 -
B locus n = 121 n = 34 n = 297
35:01 21 (17.4) 2 (5.9) 24 (8.1) 3.4 (0.7–15.1) 0.093 - 2.4 (1.3–4.5) 0.008 0.144 0.7 (0.2–3.1) P>0.99 -
38:02 25 (20.7) 9 (26.5) 91 (30.6) 0.7 (0.3–1.7) 0.475 - 0.6 (0.4–1.0) 0.0375 0.675 0.8 (0.4–1.8) 0.634 -
58:01 4 (3.3) 1 (2.9) 28 (9.4) 0.5 (0.1–3.1) 0.613 - 0.3 (0.1–1.0) 0.0273 0.491 0.3 (0.04–2.2) 0.336 -
DRB1 locus n = 120 n = 33 n = 300
03:01 3 (2.5) 3 (3.0) 24 (8) 0.8 (0.08–8.2) >0.99 - 0.3 (0.09–1.0) 0.0315 0.441 0.4 (0.05–2.7) 0.490 -
aThe number for each locus shows the number of successfuly typed samples
bCorected P-values (Pc) were only calculated for loci with P-values less than 0.05
doi:10.1371/journal.pone.0115619.t003
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among other causes [27–28]. Hepatomegaly is a significant finding in other Asian patients with
DHF or DSS [12,29–30], but is present in only a smal proportion in our study population
(4.5%,Table 1). Reports from early dengue outbreaks in the Philippines in 1966 and 1983 also
showed a similar low level of hepatomegaly in the patients studied [31–32]. These findings sug-
gest that hepatomegaly is not a major contributor to abdominal pain in our study. As abdomi-
nal pain is a consistent finding in dengue patients in the Philippines, future studies should
investigate the possible causes of this further.
In this study, under the clinical seting of increasing number of severe cases, we aimed to
identify HLA A, B and DRB1 aleles that are associated with development of dengue in a popu-
lation of Filipino children living in 2 cities in Metro Manila, the urban capital of the Philip-
pines. We compared the alele frequencies of patients with severe dengue (DHF/DSS), dengue
patients with shock (DSS) and those with mild dengue (DF) to age-matched background popu-
lation who never had symptomatic dengue. In this background population, 8/300 (2.7%) were
seropositive to dengue IgG antibodies at the time of the study. Our results present the first
evidence of host genetic factors which may be associated with protection against dengue in
the Filipino population. Various studies have implicated HLA Class I and I aleles which are
associated with susceptibility and protection against severe forms of dengue [13–15]. In our
study, HLA-A33:01 conferred protection against severe dengue, as shown by the decreased
frequency of this alele in patients which developed severe dengue (DHF/DSS) compared
to the background population (OR = 0.2,Pc= 0.0022) as wel as in patients who developed
shock compared to the background population (OR = 0.6,Pc= 0.0044). Even the non-severe
dengue group (DF) showed a tendency to be decreased in their HLA-A33:01 frequency com-
pared to the background population. Lokeet alalso reported that Vietnamese children with
HLA-A33 were less likely to develop DHF [16]. Recently, a similar tendency was also ob-
served by Appannaet alin the Indian DHF patient group in Malaysia [33], although this was
not statisticaly significant.
When HLA-A 33:01 was analyzed for linkage disequilibrium with aleles in other loci
found in this study to have a similar tendency in dengue patients (i.e., protection against severe
dengue), we found that HLA-B58:01 and HLA-DRB103:01 are in linkage disequilibrium
with A33:01 (data not shown). The A33-B58 and A33-DRB103 haplotypes were previ-
ously reported to be common in a minority population in Inner Mongolia [34]. Since the asso-
ciation of dengue with B58:01 and DRB103:01 aleles in this study was lost after Bonferroni
correction, the association is probably due to A33:01, which remained even after correction.
A33 belongs to the HLA-A3 supertype family, which includes the alelic products of at least 5
common HLA-A aleles, A3, A11, A31, A33 and A68. These aleles are grouped based on struc-
tural similarities and peptide binding motif analysis [35]. However, we did not find an associa-
tion between the other HLA-A3 supertype aleles and dengue in this study. Dengue-specific
peptides that restrict HLA-A33 have been identified; a possible mechanism of protection for
CD8 T-cels, which were shown to be restricted by this alele, is to limit viral infection by cytol-
ysis of infected cels and secretion of antiviral cytokines [16].
AlthoughHLA-A 33:01 was the only alele which reached statistical significance after cor-
rection in this study, other aleles were also found to either increase or decrease in the patient
groups compared to the background population group, but were not significant after correc-
tion. HLA-A02:03 increased in frequency in DF compared to the background population
group (OR = 5.6,P=0.021). This alele was previously reported by Stephenset alto be in-
creased in frequency in DF patients with secondary dengue infections when compared to either
controls or DHF patients with secondary infections in Thailand [36]. In this study, HLA-
B07:05 was associated with a reduced risk of developing severe dengue (DHF/DSS), HLA-B
aleles 38:02 and 58:01 were associated with a reduced risk of developing both severe dengue
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(DHF/DSS) and DSS, and HLA-B48:01 was reduced in the DF compared to the background
population group. HLA-B07 was also found at a very low frequency in patients with shock
compared to those who did not develop shock and the normal population in Sri Lanka [37]
and B58 was found at lower frequencies in DHF patients of Malay, Chinese and Indian origins
in Malaysia [38], although this was not statisticaly significant in both studies. However, in con-
trast, HLA-B48 was detected in higher frequencies in Malay and Chinese DHF patients in the
same study in Malaysia, although this was also not significant [38]. Our study also found HLA-
B35:01 to be increased in the severe dengue and DSS groups, and HLA-B51:01 to be in-
creased in the severe dengue group compared to the background population. The role of HLA-
B35:01 in dengue is uncertain as difering associations were found in previous reports. Brown
et al(2011) reported a statisticaly significant increase in B35 dengue cases compared to con-
trols in a Jamaican population, although this finding did not remain significant after correction
[39]. In contrast, a study on Mexican Mestizo patients found that B35 was negatively associat-
ed with symptomatic dengue and DF [40]. HLA-B51 was also associated with the develop-
ment of DHF in ethnic Thai patients with secondary dengue infections [36]. Two HLA Class I
aleles, HLA-DRB103:01 and DRB112:02, were also associated with dengue in our study
population, although the significance was lost after correction. The frequency of DRB103:01
was decreased in al the dengue groups- severe dengue (DHF/DSS), DSS and DF, when com-
pared to the background population, while DRB112:02 was associated with a higher risk of
developing severe dengue (OR = 1.6,P=0.0256). As mentioned earlier, DRB103:01 has sig-
nificant linkage with A33:01. Malavigeet al(2011) reported an association of DRB112 alele
with the development of DHF during primary dengue infections in Sri Lanka [37]. Although
the associations of these HLA Class I and I aleles to dengue were lost after Bonferroni correc-
tion, most of these aleles were previously reported to be associated with the development or
protection to dengue disease. Since it is possible that the loss of significance may be a conse-
quence of statistical analysis, additional studies with larger sample sizes are necessary in order
to clarify their role in susceptibility or protection in dengue disease.
The results of our study showed HLA-A33:01 as a possible protective alele for severe
dengue, which supports previous reports of host genetic factors afecting disease severity.
Other factors have also been implicated in disease severity, including secondary dengue virus
infection and the infecting viral serotype. In our study, majority of our patients (78.5%) had
secondary dengue infection based on IgG/IgM ratio. We found that a significantly higher
proportion of patients with DSS had secondary infection compared to DF patients (OR = 2.65,
P=0.005). This is consistent with studies that correlate secondary infection and disease se-
verity [8–9,41]. However, we did not find any diference between DSS and DHF patients,
or between DHF and DF. During the study period, 2008 to 2009, we detected al 4 dengue
serotypes, with Den-3 as the predominant circulating serotype (73.1%), folowed by Den-2
(19.2%). We were able to amplify and subsequently obtain serotype data for 52% of our pa-
tients, which is relatively high, consideringthat most of the blood samples were colected
after Day 5 of ilness. Although previous reports have correlated disease severity and viral
serotype [10,41], we did not find any association between the infecting serotype and disease
severity in our study.
In conclusion, our study supports previous findings implicating HLA-A33:01 in pro-
tection against the severe form of dengue, and presents the first evidence of HLA asso-
ciation with dengue in the Philippines. We recommend future studies to investigate
possible mechanisms of protection in order to contribute to a beter understanding of
dengue immunopathogenesis.
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